Deciphering the Functional Mechanisms of eIF3f in Tumors and Exploring Targeted Therapies

Yujinpeng Hao1, Jun Shao1, Naqi Lian2

  • 1The First Clinical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

Insights

Eukaryotic translation initiation factor 3 subunit F (eIF3f) has dual roles in cancer, acting as an oncogene in some cancers and a tumor suppressor in others. Understanding its context-dependent functions is key for developing targeted therapies.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • Eukaryotic translation initiation factor 3 subunit F (eIF3f) is integral to the eIF3 complex, influencing cell proliferation, apoptosis, and transcription.
  • Aberrant eIF3f expression is observed in various cancers, with a context-dependent role in tumor progression.

Purpose of the Study:

  • To systematically review the structural characteristics, biological functions, and expression patterns of eIF3f across malignancies.
  • To propose a mechanistic framework for eIF3f's functional plasticity and evaluate its potential as a biomarker.
  • To identify challenges and future directions for eIF3f-targeted cancer therapies.

Main Methods:

  • Systematic literature review and analysis of eIF3f's role in different cancer types.
  • Integration of data on eIF3f expression, post-translational modifications, and tumor microenvironment interactions.
  • Critical evaluation of diagnostic/prognostic biomarker potential and therapeutic targeting strategies.

Main Results:

  • eIF3f exhibits oncogenic roles in hepatocellular carcinoma, colorectal cancer, and prostate cancer, but tumor-suppressive functions in pancreatic cancer and melanoma.
  • Functional plasticity is attributed to differential upstream signaling, post-translational modifications, and tumor microenvironment remodeling.
  • Evidence for eIF3f as a biomarker is variable, with challenges in current therapeutic strategies.

Conclusions:

  • eIF3f's dual role necessitates context-specific understanding for effective therapeutic strategies.
  • Further research into eIF3f's structural biology and context-dependent mechanisms is crucial.
  • Developing precision, stratified therapeutic approaches for eIF3f is a priority for clinical translation.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...